Pharmacological inhibition of MDM2 enhances dendritic cell activation, increases CD8+ T cell cytotoxicity, and shifts the CD8+/Treg balance to favor anti-tumor immunity (Wang HQ. The gene discussed is CD8A; the disease is neoplasm.